Literature DB >> 15480566

Renal transplantation in patients with abdominal aortic aneurysm--a new surgical approach.

Milos Adamec1, Ivan Matia, Libor Janousek, Jiri Fronek, Petr Bachleda, Jiri Lácha, Ondrej Viklický.   

Abstract

An increasing number of abdominal aortic aneurysms occurs in renal failure patients because of an accelerated atherosclerosis process associated with uraemia. When technically feasible, endovascular repair of an abdominal aortic lesion should be considered as the treatment of choice. If a surgical repair is suggested, there are several options to select from. Since November 1999, we performed simultaneous aortic reconstruction using fresh arterial allograft and kidney transplantation in five uraemic patients with asymptomatic abdominal aortic aneurysm. The operative and postoperative course of four patients passed without major complications. One patient had ischaemic colitis early after the operation, which required a partial resection of the colon. One patient died 6 weeks after the operation due to non-vascular causes. In conclusion, the advantage of our single-phase procedure is that both diseases are treated simultaneously during a single hospital stay. Moreover, with our procedure, the risk of vascular graft infection in patients with chronic immunosuppression is low.

Entities:  

Mesh:

Year:  2004        PMID: 15480566     DOI: 10.1007/s00147-004-0764-x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  Ischemic colitis due to obstruction of mesenteric and splenic veins: a case report.

Authors:  Seong-Su Hwang; Woo-Chul Chung; Kang-Moon Lee; Hyun-Jin Kim; Chang-Nyol Paik; Jin-Mo Yang
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

2.  Immunosuppressive protocols with tacrolimus after cryopreserved aortal allotransplantation in rats.

Authors:  Rudolf Spunda; Jan Hruby; Pavel Mericka; Mikulas Mlcek; Ondrej Pecha; Kathrin Splith; Moritz Schmelzle; Felix Krenzien; Jaroslav Lindner; Ivan Matia; Miroslav Spacek
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.